Technoderma Medicines Advances JAK1/Tyk2 Inhibitor in AD Clinical Program
Technoderma Medicines, Inc.’s is now dosing atopic dermatitis (AD) patients in its Phase 2a clinical trial of topical TDM-180935 ointment. TDM-180935 is a Janus Kinase 1 (JAK1)/tyrosine-protein kinase 2 (TYK2) small molecule inhibitor. This clinical trial includes eight weeks dosing of two different active formulation strengths and placebo. It is a randomized, vehicle-controlled, parallel group comparison study with an open-label pharmacokinetic sub-study. Objectives are to evaluate the safety and efficacy of topical TDM-180935 as well as […]